T
Thor Medical
Supplier of high-purity alpha-emitting isotopes (Pb-212, Th-228, Ra-224) for targeted cancer therapies
About Thor Medical
Thor Medical ASA is a Norwegian producer and supplier of high-purity alpha-emitting radioisotopes for the radiopharmaceutical industry. Its product portfolio comprises lead-212 (Pb-212) and its precursor isotopes thorium-228 (Th-228) and radium-224 (Ra-224), supplied to early-stage biotech companies, CDMOs and pharmaceutical companies developing targeted alpha therapies for cancer. The company's proprietary process applies separation technology to naturally occurring thorium (Th-232) and requires neither irradiation nor nuclear reactors.
After validating the process through pilot production and customer deliveries from 2024, Thor Medical started commercial production in July 2026 at AlphaOne, its industrial-scale facility at Herøya Industrial Park in Norway, and completed its first customer delivery from the plant, of Th-228, in August 2026. Capacity is planned to ramp up to around 21,000 patient dose equivalents after three years.
The listed company was founded in 2009 as Nordic Nanovector ASA, a developer of antibody-radionuclide conjugates for haematological cancers, whose lead candidate Betalutin was discontinued in 2022. On 3 July 2023 Nordic Nanovector completed the all-share acquisition of 100% of Thor Medical AS, founded in 2017 by Scatec Innovation, issuing 116,769,503 new shares to its shareholders, and was renamed Thor Medical ASA, trading on Oslo Børs under the ticker TRMED. The former Nordic Nanovector patent portfolio was transferred to NucliThera AS with effect from 1 December 2023, with Thor Medical retaining a profit-sharing interest. The company is headquartered in Oslo.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2015
- Employees
- 23
- Open positions
- None listed
- Dealroom signal
- 89.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Oncology, Drug Development, Spinout, Biotech and Pharma, Horizon Europe, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Investment activity
- 1 company, latest Jun 2023
- Capital deployed
- —
- Preferred round
- ACQUISITION
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Jun 2025 | $1.4M | — | Undisclosed | ↗ |
| PRIVATE PLACEMENT NON VCOther financing | Jun 2025 | $9.1M | — | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Thor Medical is 3.6K monthly website visits, down 20% over the last three months. Thor Medical's team grew 43.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Thor Medical in the Oslo ecosystem
The Thor Medical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Birk Venture
Research Council of Norway
Other known investors3 additional known investors
Inven2
University of Oslo
HealthCap
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Thor Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Thor Medical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









